Gene Profiling of High Risk Neuroblastoma
Authors:
- 10 February 2005
- journal article
- review article
- Published by Wiley in World Journal of Surgery
- Vol. 29 (3) , 317-324
Abstract
Neuroblastoma, a cancer of young children, is well known for its diverse pattern of presentation. Approximately one-half of children have localized tumors that can be cured with surgery alone. The remaining children have widespread metastatic disease or quite large, aggressive, localized tumors. These children have a poor long-term survival rate of approximately 30%. We review the prognostically significant histologic and molecular features of high risk neuroblastoma and propose an algorithm to dissect further the differentially expressed genes that define the phenotype of this disease. Over the past 25 years, much effort has gone into establishing reliable prognostic indicators of high risk disease. For neuroblastoma, age, stage, and histopathology have time and again correlated well with outcomes. Chromosomal number, or ploidy, and amplification of the MYCN oncogene have proved to be equally as important and are commonly used to stratify patient risk. Other potentially lucrative markers include chromosome 1p deletion, chromosome 17q gain, receptor tyrosine kinases A and B (trk-A, trk-B), CD44, CXCR4, and multidrug resistance associated protein (MRP). With the onset of new technology, expression microarrays are now being used to profile advanced-stage neuroblastoma on a larger scale. Genes particular to cell cycle control, DNA/RNA replication, ribosomal synthesis, neuronal differentiation, and intracellular/extracellular signal transduction have been identified through differential expression analysis. We present our research on the MYCN transcription factor and target gene, MCM7, to show the utility of this approach.Keywords
Funding Information
- U.S. Public Health Service (CA 78456)
This publication has 75 references indexed in Scilit:
- Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982–1992European Journal of Cancer, 2000
- Gene-target recognition among members of the Myc superfamily and implications for oncogenesisNature Genetics, 2000
- The international neuroblastoma risk groups (INRG): a preliminary reportEuropean Journal of Cancer, 1997
- Genetic Staging of Unresectable or Metastatic Neuroblastomain Infants: a Pediatric Oncology Group StudyJNCI: Journal of the National Cancer Institute, 1997
- A population-based study of the usefulness of screening for neuroblastomaThe Lancet, 1996
- Molecular basis for heterogeneity in human neuroblastomasEuropean Journal of Cancer, 1995
- Neuroblastoma: a clinical challenge and biologic puzzleCA: A Cancer Journal for Clinicians, 1995
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985
- Cellular DNA Content as a Predictor of Response to Chemotherapy in Infants with Unresectable NeuroblastomaNew England Journal of Medicine, 1984
- Surgicopathologic staging of neuroblastoma: Prognostic significance of regional lymph node metastasesThe Journal of Pediatrics, 1983